Drug Information

General Information
Drug ID
DR00223
Drug Name
Rosuvastatin
Synonyms
(3R,5S,6E)-7-(4-(4-fluorophenyl)-6-(1-methylethyl)-2-(ethyl(methylsulfonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy-6-heptenoic acid; (3R,5S,6E)-7-{4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-(propan-2-yl)pyrimidin-5-yl}-3,5-dihydroxyhept-6-enoic acid; (3R,5S,6E)-7-{4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl}-3,5-dihydroxyhept-6-enoic acid; (E,3R,5R)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid; (E,3R,5S)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid; (S-((R*,S*-(E)))-7-(4-(4-fluorophenyl)-6-(1-methylethyl)-2-(methyl(methylsulfonyl) amino)-5-pyrimidinyl)-3,5-dihydroxy-6-heptenoic acid, calcium salt (2:1); (S-(R*,S*-(E)))-7-(4-(4-Fluorophenyl)-6-(1-methylethyl)-2-(methyl(methylsulfonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy-6-heptenoic acid, calcium salt (2:1); 6-Heptenoic acid, 7-(4-(4-fluorophenyl)-6-(1-methylethyl)-2-(ethyl(methylsulfonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy-, (3R,5S,6E); 6-Heptenoic acid, 7-(4-(4-fluorophenyl)-6-(1-methylethyl)-2-(methyl(methylsulfonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy-, calcium salt (2:1), (3R,5S,6E); AZD-4522; Astende; Bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino] pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhelpt-6-enoic acid] calcium salt; Calcium (E,3R,5S)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoate; Cirantan; Cresadex; Creston; Creston (TN);Crestor (TN); Crestor; Provisacor; Pyrimidine Compound, 26; Razel; Rosedex; Rosimol; Rosumed; Rosustatin; Rosuvas; Rosuvast; Rosuvastatin (INN); Rosuvastatin [INN]; Rosuvastatin calcium; Rosuvastatin calcium (JAN/USAN); Rosuvastatin calcium [USAN]; Rosuvastatin hemicalcium; Rosvel; Rovartal; S 4522; S-4522; Simestat; Sinlip; Vivacor; ZD 4522; ZD 4522, calcium salt; ZD-4522; ZD4522
Drug Type
Small molecular drug
Indication Hypercholesterolemia [ICD11: 5C80.0] Approved [1]
Therapeutic Class
Anticholesteremic Agents
Structure
3D MOL 2D MOL
Formula
C22H28FN3O6S
Canonical SMILES
CC(C)C1=NC(=NC(=C1C=CC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)N(C)S(=O)(=O)C
InChI
InChI=1S/C22H28FN3O6S/c1-13(2)20-18(10-9-16(27)11-17(28)12-19(29)30)21(14-5-7-15(23)8-6-14)25-22(24-20)26(3)33(4,31)32/h5-10,13,16-17,27-28H,11-12H2,1-4H3,(H,29,30)/b10-9+/t16-,17-/m1/s1
InChIKey
BPRHUIZQVSMCRT-VEUZHWNKSA-N
CAS Number
CAS 287714-41-4
Pharmaceutical Properties Molecular Weight 481.5 Topological Polar Surface Area 149
Heavy Atom Count 33 Rotatable Bond Count 10
Hydrogen Bond Donor Count 3 Hydrogen Bond Acceptor Count 10
XLogP
1.6
PubChem CID
446157
PubChem SID
10299840 , 103556348 , 104635880 , 104829200 , 124637938 , 126680774 , 126731182 , 127315738 , 127315739 , 127315740 , 127315741 , 127315742 , 127315743 , 127315744 , 127315745 , 127315746 , 127315747 , 127315748 , 127315749 , 127315750 , 127315751 , 127315752 , 127315753 , 127315754 , 127315755 , 127315756 , 127315757 , 127315758 , 135084331 , 135650928 , 135723476 , 14810118 , 14834808 , 24775831 , 26612833 , 26680899 , 36888655 , 46509022 , 46518448 , 47960010 , 48035409 , 50070881 , 50122666 , 53790555 , 57404725 , 80442666 , 822168 , 88531873 , 92124833 , 96025178
ChEBI ID
ChEBI:38545
TTD Drug ID
D0JE2E
DT(s) Transporting This Drug BCRP Transporter Info Breast cancer resistance protein Substrate [2]
MRP2 Transporter Info Multidrug resistance-associated protein 2 Substrate [2]
NTCP Transporter Info Sodium/taurocholate cotransporting polypeptide Substrate [3]
OAT3 Transporter Info Organic anion transporter 3 Substrate [4]
OATP1A2 Transporter Info Organic anion transporting polypeptide 1A2 Substrate [3]
OATP1B1 Transporter Info Organic anion transporting polypeptide 1B1 Substrate [2]
OATP1B3 Transporter Info Organic anion transporting polypeptide 1B3 Substrate [2]
OATP2B1 Transporter Info Organic anion transporting polypeptide 2B1 Substrate [2]
P-GP Transporter Info P-glycoprotein 1 Substrate [2]
Drug-Transporter Activity Data
Drug-Transporter Activity Data BCRP Transporter Info Km = 2.02 microM Human embryonic kidney cells (HEK293)-BCRP [2]
BCRP Transporter Info Km = 10.1 microM Madin-Darby canine kidney cells (MDCKII)-BCRP [5]
NTCP Transporter Info Km = 65 microM Human cervical cancer cell line (Hela)-NTCP [3]
OAT3 Transporter Info Km = 7.4 microM Oocytes-OAT3 [4]
OATP1A2 Transporter Info Km = 2.6 microM Human cervical cancer cell line (Hela)-OATP1A2 [3]
OATP1B1 Transporter Info Km = 4 microM Human cervical cancer cell line (Hela)-OATP1B1 [3]
OATP1B1 Transporter Info Km = 7.3 microM Human cervical cancer cell line (Hela)-OATP1B1 [3]
OATP1B1 Transporter Info Km = 0.8 microM Human embryonic kidney cells (HEK293)-OATP1B1 [2]
OATP1B1 Transporter Info Km = 8.5 microM Oocytes-OATP1B1 [6]
OATP1B3 Transporter Info Km = 9.8 microM Human cervical cancer cell line (Hela)-OATP1B3 [3]
OATP1B3 Transporter Info Km = 14.2 microM Human embryonic kidney cells (HEK293)-OATP1B3 [2]
OATP2B1 Transporter Info Km = 2.4 microM Human cervical cancer cell line (Hela)-OATP2B1 [3]
OATP2B1 Transporter Info Km = 6.42 microM Human embryonic kidney cells (HEK293)-OATP2B1 [2]
References
1 Rosuvastatin was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos. 2008 Oct;36(10):2014-23.
3 Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology. 2006 May;130(6):1793-806.
4 The contribution of organic anion transporters OAT1 and OAT3 to the renal uptake of rosuvastatin. J Pharmacol Exp Ther. 2007 Sep;322(3):1221-7.
5 Effect of silymarin supplement on the pharmacokinetics of rosuvastatin. Pharm Res. 2008 Aug;25(8):1807-14.
6 Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther. 2004 Aug;76(2):167-77.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.